


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF NEW DRUG APPLICATION FOR
TQB3909 TABLET “BCL-2 INHIBITOR”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a new drug application for Category 1 innovative drug TQB3909 Tablet “BCL-2 Inhibitor” independently developed by the Group subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (“**CTTQ**”), has been submitted to and accepted by the Center for Drug Evaluation (CDE) of the China’s National Medical Products Administration, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a BTK inhibitor.

TQB3909 is a BCL-2 inhibitor independently developed by the Group. By binding to the BCL-2 protein, it releases pro-apoptotic proteins such as BAK, BAX and BAD, promotes the release of mitochondrial cytochrome c, induces phosphatidylserine externalization, and stimulates caspase-3/7 activity as well as caspase-3/9 cleavage, thereby inducing apoptosis.

This marketing application is based on a single-arm, open-label, multicenter Phase II registrational clinical trial designed to evaluate the efficacy and safety of TQB3909 in patients with relapsed or refractory CLL/SLL. The study results showed that TQB3909 demonstrated significant efficacy and a manageable safety profile in CLL/SLL patients who had received at least one prior systemic therapy, including a BTK inhibitor. Compared with currently available treatment options in China, TQB3909 offers significant clinical benefits.

CLL/SLL is a clonal proliferative neoplasm of mature B lymphocytes that predominantly affects the middle-aged and elderly populations. It is characterized by specific immunophenotypic markers. The median survival is approximately 10 years, but the prognosis exhibits considerable heterogeneity across patients. For patients with relapsed or refractory CLL/SLL, particularly those who have developed resistance or intolerance to BTK inhibitors, current treatment options are extremely limited, resulting in significantly reduced overall survival (OS) and progression-free survival (PFS).

TQB3909 was granted Priority Review designation by the CDE in July 2026. The steady progress of this marketing application is expected to provide a superior treatment option for patients with relapsed/refractory CLL/SLL. Moving forward, the Group will continue to deepen its efforts in precision oncology, increase investment in original innovation, and remain committed to providing the clinical community with innovative drugs with superior efficacy and higher quality, thereby benefiting a wide range of patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 4 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.